Tetrahydrobiopterin synthesis and inducible nitric oxide production in pulmonary artery smooth muscle. 1994

D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
Department of Surgery, University of North Carolina at Chapel Hill 27599-7210.

We recently reported (Am. J. Respir. Cell Mol. Biol. 7: 471-476, 1992) that a mixture of lipopolysaccharide (LPS) and cytokines produced a time-dependent increase in mRNA and protein expression of inducible nitric oxide synthase (iNOS) in cultured rat pulmonary artery smooth muscle cells (RPASM). In the current study we extend observations on regulation of iNOS in RPASM by showing that de novo synthesis of tetrahydrobiopterin (BH4) is critical for LPS and cytokine-induced NO production. A mixture of LPS and the cytokines gamma-interferon, interleukin-1 beta, and tumor necrosis factor-alpha increased steady-state levels of mRNA of GTP-cyclohydrolase-I (GTP-CH), the rate-limiting enzyme in BH4 biosynthesis. Levels of mRNA to GTP-CH became detectable by 4 h, with further increases at 24 h by Northern blot analysis and reverse-transcriptase polymerase chain reaction. Total intracellular biopterin levels, undetectable under basal conditions, increased after 24 h exposure to LPS and cytokines (to 32.3 +/- 0.8 pmol/mg protein). LPS and cytokine-induced NO production, determined by nitrite concentrations in the medium, was decreased in a concentration-dependent manner by the GTP-CH inhibitor, 2,4-diamino-6-hydroxypyrimidine (DAHP) at 24 h. DAHP also inhibited completely the LPS- and cytokine-induced accumulation of intracellular biopterins. Sepiapterin, which supplies BH4 through a salvage pathway independent of GTP-CH, reversed the effect of DAHP on LPS and cytokine-induced NO production.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007042 Hypoxanthines Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism.
D007425 Intracellular Membranes Thin structures that encapsulate subcellular structures or ORGANELLES in EUKARYOTIC CELLS. They include a variety of membranes associated with the CELL NUCLEUS; the MITOCHONDRIA; the GOLGI APPARATUS; the ENDOPLASMIC RETICULUM; LYSOSOMES; PLASTIDS; and VACUOLES. Membranes, Intracellular,Intracellular Membrane,Membrane, Intracellular
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D009573 Nitrites Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M Nitrite
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006136 GTP Cyclohydrolase (GTP cyclohydrolase I) or GTP 7,8-8,9-dihydrolase (pyrophosphate-forming) (GTP cyclohydrolase II). An enzyme group that hydrolyzes the imidazole ring of GTP, releasing carbon-8 as formate. Two C-N bonds are hydrolyzed and the pentase unit is isomerized. This is the first step in the synthesis of folic acid from GTP. EC 3.5.4.16 (GTP cyclohydrolase I) and EC 3.5.4.25 (GTP cyclohydrolase II). GTP 8-Formylhydrolase,GTP Dihydrolase,GTP Ring-Opening Enzyme,7,8-Dihydroneopterintriphosphate Synthetase,GTP Cyclohydrolase I,GTP Cyclohydrolase II,7,8 Dihydroneopterintriphosphate Synthetase,8-Formylhydrolase, GTP,Cyclohydrolase I, GTP,Cyclohydrolase II, GTP,Cyclohydrolase, GTP,Dihydrolase, GTP,GTP 8 Formylhydrolase,GTP Ring Opening Enzyme,Ring-Opening Enzyme, GTP,Synthetase, 7,8-Dihydroneopterintriphosphate

Related Publications

D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
April 1999, The Journal of surgical research,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
August 1996, Seminars in pediatric surgery,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
February 1998, Biochemical and biophysical research communications,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
January 1993, Advances in experimental medicine and biology,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
June 2000, Prostaglandins, leukotrienes, and essential fatty acids,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
September 2002, Critical care medicine,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
January 1992, Japanese journal of pharmacology,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
February 2013, International journal of molecular sciences,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
March 1994, Arzneimittel-Forschung,
D K Nakayama, and D A Geller, and M Di Silvio, and G Bloomgarden, and P Davies, and B R Pitt, and K Hatakeyama, and H Kagamiyama, and R L Simmons, and T R Billiar
January 1996, Life sciences,
Copied contents to your clipboard!